Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > March 31, 2023
Daily News
March 31, 2023
- Ultragenyx Plans Japan Submission of Evinacumab in May: CEO
March 31, 2023
- Takeda’s Iwasaki to Retire as Representative Director
March 31, 2023
- Pfizer Japan Files 20-Valent Pneumococcal Vaccine for Pediatric Use
March 31, 2023
- Sanofi Launches PD-1 Inhibitor Libtayo in Japan
March 31, 2023
- Suprapartisan Lawmakers’ League Discussing Bill to Establish Dementia Law
March 31, 2023
- JCR, Alexion Pair Up for Neurodegenerative Disease
March 31, 2023
- LDP League Asks Health Minster for Proper Insurance Coverage for Patches
March 31, 2023
- AMED’s “CANNDs” Set for Full Rollout in FY2023, but Panel Members Want Wider Range of Data to Fuel Drug Discovery
March 31, 2023
- Twymeeg Tops GP Promotion Ranking 2 Months Running, Belsomra Most Detailed among HPs in February
March 31, 2023
- Merck Poised to Work Together with Japan towards 90% HPV Vaccine Rate: Exec
March 31, 2023
- The Increasing Impact of Real-World Evidence
March 31, 2023
Japan’s pharmaceutical industry could be on the verge of gaining a stronger voice in the Central Social Insurance Medical Council…
Let’s face it: in today’s world, changing jobs is a normal part of a successful career. But if it’s so normal, why does it feel so hard? For many people, the idea of leaving their current role brings a heavy…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…